All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021
Home » Blogs » BioWorld MedTech Perspectives » MIS2013 coverage in 140 characters or less!

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

MIS2013 coverage in 140 characters or less!

Oct. 21, 2013
By Amanda Pedersen
No Comments

Love it or hate it, social media has become ingrained in most of our lives both personally and professionally. LinkedIn has made it easier than ever for professionals across business sectors to connect with one another and forge potential working relationships. And for those of us in the news business—especially those of us covering the ever volatile healthcare industry —the rise of Twitter has both enabled and demanded the delivery of real-time news in 140 characters or less.

The influence that social media, Twitter in particular, has on our professional lives was blatantly apparent in Cleveland last week where nearly 1,600 industry stakeholders gathered for the Cleveland Clinic’s 11th annual Medical Innovation Summit. This year’s meeting also served as the inaugural event at the Global Center for Health Innovation in Cleveland’s downtown.

This year, conference organizers went out of their way to encourage participants to “join the conversation” by displaying a scrolling Twitter feed on the screens behind the panel speakers. They also ran a friendly competition for Tweeting the best picture from the Tuesday night reception, which Medical Device Daily’s Executive Director Don Johnston proudly won, taking home an iPad Mini for his efforts. MDD also ranked fourth on a list of Top 10 Twitter mentions (the top three on that list

Cleveland's iconic Terminal Tower and the city's brand new Global Center for Health Innovation.
Cleveland's iconic Terminal Tower and the city's brand new Global Center for Health Innovation.

were all affiliated with the Cleveland Clinic and involved with the organization of the event).

Of course not everyone is a fan of social media. In fact, one over-served attendee at the networking reception Tuesday night was quick to express—using no uncertain terms—his dislike for the prominent display of Tweets running throughout the sessions. While it might have been seen as a distraction to some, the fact remains that Twitter, much like LinkedIn, has a legitimate place in the business world.

And in case you missed the conversation last week, here are some highlights from MDD’s Twitter coverage of the Medical Innovation Summit:

  • “We’re thinking of the post-EMR era of healthcare” – IBM Global Healthcare’s Sean Hogan on health IT panel.
  • Covidien CEO Almeida, native of Brazil, says obesity has become global challenge & “not just a developed country issue anymore.”
  • Transparency about cost is new for all in healthcare, representing significant challenge in changing environment. – Dr. [Toby] Cosgrove.
  • Obesity leads to orthopedic & other complications, says Cleveland Clinic’s Steve Niessen. “Every system in the body is affected.”
  • How will obesity market evolve? We don’t know. Lots of resistance (at FDA) to call it a disease. – Brian Dovey, Domain Associates.
  • Dr. [Michael] Roizen’s vision of a good solution to metabolic crises: prevention. Can we intervene earlier and save the whole system money?
  • Michael Roizen, MD, on investing in metabolic disorders: So much unmet need in the U.S. that there will be a lot of winners.
  • J&J’s Brad Vale says metabolic disorders is a great area to invest in, but regulatory hurdles makes the decision tough.
  • Corp. America should remove small impediments, says Citibank’s [Peter] Orszag. Put fruits/veggies at front of cafeteria line; offer onsite gyms.
  • “We’ve never needed innovation in this country more than we do now.” – Former Sen. [Tom] Daschle on challenges facing U.S. healthcare.
You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing